期刊
BRAIN TUMOR PATHOLOGY
卷 33, 期 3, 页码 161-168出版社
SPRINGER JAPAN KK
DOI: 10.1007/s10014-016-0265-5
关键词
Genetic-metabolism interaction; IDH; Glioma; Metabolic reprogramming; RTK; Molecular genetics
资金
- National Institute for Neurological Diseases and Stroke Grant [NS73831]
- Defeat GBM Research Collaborative of National Brain Tumor Society
- National Cancer Institute [CA119347]
- Ben and Catherine Ivy Foundation
- Novartis Foundation (Japan)
- Cell Science Research Foundation
- Tokyo Biochemical Research Foundation
- JSPS KAKENHI [15K19067]
- Grants-in-Aid for Scientific Research [15K19067] Funding Source: KAKEN
The recent identification of distinct genetic and epigenetic features in each glioma entity is leading to a multilayered, integrated diagnostic approach combining histologic features with molecular genetic information. Somatic mutations in isocitrate dehydrogenase (IDH) and receptor tyrosine kinase (RTK) pathways are key oncogenic events in diffuse gliomas, including lower grade (grade II and III) gliomas (LGG) and the highly lethal brain tumor glioblastoma (GBM), respectively, where they reprogram the epigenome, transcriptome, and metabolome to drive tumor growth. However, the mechanisms by which these genetic aberrations are translated into the aggressive nature of gliomas through metabolic reprogramming have just begun to be unraveled. The intricate interactions between the oncogenic signaling and cancer metabolism have also been recently demonstrated. Here, we describe a set of recent discoveries on cancer metabolism driven by IDH mutation and mutations in RTK pathways, highlighting the integration of genetic mutations, metabolic reprogramming, and epigenetic shifts, potentially providing new therapeutic opportunities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据